Evidence map›Paper›PMID 34286904›Full record

ArticleCancer science2021

MYB mediates downregulation of the colorectal cancer metastasis suppressor heterogeneous nuclear ribonucleoprotein L-like during epithelial-mesenchymal transition.

Keiichiro Sakuma, Eiichi Sasaki, Waki Hosoda, Koji Komori, Yasuhiro Shimizu, Yasushi Yatabe, Masahiro Aoki

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. [High expression of MYBL2 promotes progression and predicts a poor survival outcome of prostate cancer].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Keiichiro SakumaDivision of Pathophysiology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Eiichi SasakiDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.
Waki HosodaDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.
Koji KomoriDepartment of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Yasuhiro ShimizuDepartment of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Yasushi YatabeDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0003-1788-559X
Masahiro AokiDivision of Pathophysiology, Aichi Cancer Center Research Institute, Nagoya, Japan.ORCID https://orcid.org/0000-0003-4316-9490
Aichi Cancer Center · JPTokyo National Hospital · JP

Funding

Daiko FoundationJapan Society for the Promotion of Science 16K07138Japan Society for the Promotion of Science 18H02686Japan Society for the Promotion of Science 20K07581Mochida Memorial Foundation for Medical and Pharmaceutical ResearchNagono Medical FoundationPrincess Takamatsu Cancer Research Fund, JapanTakeda Science Foundation
6 · The paper itself

Abstract

Heterogeneous nuclear ribonucleoprotein L-like (HNRNPLL), a suppressor of colorectal cancer (CRC) metastasis, is transcriptionally downregulated when CRC cells undergo epithelial-mesenchymal transition (EMT). Here we show that decrease of MYB mediates the downregulation of HNRNPLL during EMT. The promoter activity was attributed to a region from -273 to -10 base pairs upstream of the transcription start site identified by 5'-RACE analysis, and the region contained potential binding sites for MYB and SP1. Luciferase reporter gene assays and knockdown or knockout experiments for genes encoding the MYB family proteins, MYB, MYBL1, and MYBL2, revealed that MYB was responsible for approximately half of the promoter activity. On the other hand, treatment with mithramycin A, an inhibitor for SP1 and SP3, suppressed the promoter activity and their additive contribution was confirmed by knockout experiments. The expression level of MYB was reduced on EMT while that of SP1 and SP3 was unchanged, suggesting that the downregulation of HNRNPLL during EMT was mediated by the decrease of MYB expression while SP1 and SP3 determine the basal transcription level of HNRNPLL. Histopathological analysis confirmed the accumulation of MYB-downregulated cancer cells at the invasion front of clinical CRC tissues. These results provide an insight into the molecular mechanism underlying CRC progression.

Indexed as

Binding SitesCell ProliferationColorectal NeoplasmsDisease ProgressionDown-RegulationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticGene Knockdown TechniquesGene Knockout TechniquesHeterogeneous-Nuclear RibonucleoproteinsHT29 CellsHumansNeoplasm MetastasisPlicamycinPromoter Regions, GeneticProto-Oncogene Proteins c-mybHeterogeneous-Nuclear RibonucleoproteinsHNRNPLL protein, humanmithramycin APlicamycinProto-Oncogene Proteins c-mybSP1 protein, humanSp1 Transcription Factorcolorectal cancerepithelial-mesenchymal transitionHNRNPMYBSP1

Identifiers

PMID34286904
PMCPMC8409424
OpenAlexW3185298598

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.